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Hepascore combining serum bilirubin, gamma glutamyl transpeptidase, hyaluronic
acid (HA) and α2-macroglobulin with age and sex, was reported as relevant in
predicting liver fibrosis in patients with chronic HCV infection and was proposed
as an alternative to liver biopsy.
Methods
Since an automated HA assay (Latex method, Wako, Japan) became available, we
investigated to automate Hepascore by simultaneous measurements of
components using an OLYMPUS AU640 analyzer (Tokyo, Japan). For its clinical
evaluation, we considered a cohort of chronic HCV patients included in a
multicenter prospective study (ANRS HC EP 23 Fibrostar).
Results
Automated Hepascore was not significantly different than assayed as previously
described. An improvement in HA variability was evidenced. In 512 chronic HCV
patients, automated Hepascore, using ROC curves analysis, showed good
predictive performances for significant fibrosis (AUROC = 0.81), severe fibrosis
(AUROC = 0.82), and cirrhosis (AUROC = 0.88). For significant fibrosis,
Hepascore (cut-off = 0.5) had a sensitivity of 0.77, a specificity of 0.70, a positive
predictive value of 0.71 and a negative predictive value (NPV) of 0.77. Hepascore
< 0.25 could exclude significant fibrosis with a sensitivity of 0.95 and a NPV of
0.90 and Hepascore < 0.75 could exclude cirrhosis with a sensitivity of 0.86 and a
NPV of 0.97.
Conclusions
This study shows that Hepascore, a non-invasive index of liver fibrosis,
necessitating only one serum sample, can be totally automated using a single
analyzer and confirms that Hepascore accurately predicts liver fibrosis in chronic
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